KOL | Lauren Eileen AbreyNovartis, Basel, Switzerland. | Memorial Sloan Kettering Cancer Center, New York, NY, USA | Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York ... |
KOL Resume for Lauren Eileen Abrey
| Year | |
|---|---|
| 2021 | Novartis, Basel, Switzerland. |
| 2020 | Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| 2019 | Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, NY, USA Novartis Oncology, Basel, Switzerland |
| 2018 | F. Hoffman-La Roche, Ltd |
| 2017 | Hoffman-La Roche Ltd, Basel, Switzerland University Medical Center, Neuroradiology, Heidelberg, Germany. |
| 2016 | Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Saitama Medical University, Saitama, Japan (R.N.); Princess Margaret Hospital, Toronto, Canada (W.M.); Regional Cancer Center Stockholm Gotland, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden (R.H.); The Royal Marsden NHS Foundation Trust, Surrey, UK (F.S.); University of California, Los Angeles, California, USA (T.C.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (J.G., C.R., L.A.); University Medical Center, Heidelberg, Germany (W.W.). UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.) F. Hoffmann-La Roche Ltd., Basel, Switzerland; |
| 2015 | Department of Neurology, F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, Product Development Oncology, Basel, Switzerland. |
| 2014 | F. Hoffmann-La Roche, Basel, Switzerland Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York. |
| 2013 | Genentech, South San Francisco, California (K.H., M.R., A.D., J.J.); University Medical Center & DKFZ, Heidelberg, Germany (W.W.); F. Hoffmann–La Roche, Basel, Switzerland (L.A.); Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts (D.A.R.) F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland Memorial Sloan-Kettering Cancer Center |
| 2012 | Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10065, New York, NY, USA |
| 2011 | Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA Memorial Sloan-Kettering Cancer Center, New York, New York |
| 2010 | Department of Neurology, Memorial Sloan‐Kettering Cancer Center, New York, New York |
| 2009 | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI From the Brain Tumor Center, Duke University, Durham, NC and University of Utah Hospital, Salt Lake City, UT. Genetech Inc, South San Francisco |
| 2008 | Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Neurology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA |
Lauren Eileen Abrey: Influence Statistics
| Concept | World rank |
|---|---|
| pcnsl wholebrain radiotherapy | #1 |
| gynecologic malignancy result | #1 |
| therapies steroids | #1 |
| evolution neurooncology | #1 |
| bev 2 weeks | #1 |
| pcnsl potential | #1 |
| cns initial | #1 |
| elderly gbm population | #1 |
| rare subtype pcnsl | #1 |
| dosing strategy researchers | #1 |
| cns nonhodgkin methotrexate | #1 |
| vinorelbine dose 15 | #1 |
| resultsthirtyone women | #1 |
| update cns | #1 |
| wbrt recurrences | #1 |
| pcnsl bloodbrain barrier | #1 |
| cornerstone multimodality therapy | #1 |
| nbev | #1 |
| understanding complication | #1 |
| pcnsl current standard | #1 |
| patients proneural | #1 |
| intensive temozolomide | #1 |
| unusual variants pcnsl | #1 |
| dosedense metronomic temozolomide | #1 |
| corticosteroids symptomatic treatment | #1 |
| systemic lymphomas article | #1 |
| cns intrathecal chemotherapies | #1 |
| single agents pcnsl | #1 |
| standard treatment frameworks | #1 |
| systemic nonhodgkin lymphoma | #1 |
| newer regimens toxicity | #1 |
| bomes mtv | #1 |
| radiolabeled indium‐111 | #1 |
| pcnsl mci | #1 |
| complication longterm follow | #1 |
| pcnsls highgrade diffuse | #1 |
| diffuse infiltration brain | #1 |
| lipid lactate | #1 |
| numerous questions optimal | #1 |
| targeted occult disease | #1 |
| treatmentrelated neurotoxicity progress | #1 |
| discussion achievements | #1 |
| pcnsl uncommon form | #1 |
| intracranial dural metastases | #1 |
| wbrt advances | #1 |
| effective approaches disruption | #1 |
| gbm median age | #1 |
| brain pcnsl | #1 |
| pcnsl unusual variants | #1 |
| recurrent progressive bm | #1 |
Open the FULL List in Excel | |
Prominent publications by Lauren Eileen Abrey
BACKGROUND: Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma.
METHODS: We randomly assigned patients with supratentorial glioblastoma to receive intravenous bevacizumab (10 mg per kilogram of body weight every 2 weeks) or placebo, plus radiotherapy (2 Gy 5 days a week; maximum, 60 Gy) and oral ...
| Known for Bevacizumab Placebo | Newly Diagnosed Glioblastoma | Hazard Ratio | Life Monoclonal | Radiotherapy Temozolomide |
PURPOSE: The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide. To establish whether certain patient subgroups derived an OS benefit from the addition of bevacizumab to first-line standard-of-care therapy, AVAglio patients were retrospectively evaluated for ...
| Known for Retrospective Analysis | Survival Benefit | Proneural Glioblastoma | Avaglio Trial | Addition Bevacizumab |
PURPOSE: A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphoma.
PATIENTS AND METHODS: Patients received induction chemotherapy with R-MPV (five to seven cycles); those achieving a complete response (CR) received rdWBRT (23.4 Gy), and otherwise, standard WBRT was offered (45 Gy). Consolidation ...
| Known for Procarbazine Vincristine | Rituximab Methotrexate | Cns Lymphoma | Brain Radiotherapy | Patients Rdwbrt |
PURPOSE: We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
PATIENTS AND METHODS: One hundred sixty-seven patients were randomly assigned to receive bevacizumab 10 mg/kg alone or in combination with irinotecan 340 mg/m(2) or 125 mg/m(2) (with or without concomitant enzyme-inducing antiepileptic drugs, respectively) once every 2 weeks. Primary end points ...
| Known for Recurrent Glioblastoma | Bevacizumab Irinotecan | Monoclonal Antibodies | Humanized Antineoplastic | Secondary Points |
Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
[ PUBLICATION ]
PURPOSE: Preclinical studies suggest that inhibition of vascular endothelial growth factor (VEGF) improves glioma response to radiotherapy. Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of concurrent bevacizumab with brain irradiation has not been extensively studied. The objectives of this study were to determine the safety and activity of this combination in malignant gliomas.
METHODS AND MATERIALS: After prior ...
| Known for Malignant Gliomas | Monoclonal Antibodies | Bevacizumab Hfsrt | Hypofractionated Stereotactic | Brain Irradiation |
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
[ PUBLICATION ]
BACKGROUND: Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically.
METHODS: We identified patients at Memorial Sloan-Kettering Cancer Center with recurrent GBM who discontinued bevacizumab because of progressive disease.
RESULTS: There were 37 patients (26 men with a median age of 54 years). The ...
| Known for Bevacizumab Failure | Monoclonal Antibodies | Recurrent Glioblastoma Gbm | Progressive Disease | Humanized Antineoplastic |
BACKGROUND: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced nonsmall cell lung carcinoma (NSCLC). Long- term outcome and patterns of disease recurrence after response have not been described.
METHODS: The authors evaluated 139 patients with NSCLC treated with gefitinib at Memorial Sloan-Kettering Cancer Center (New York, NY) between 1998 and 2002. They focused on patterns of disease ...
| Known for Disease Recurrence | Lung Carcinoma | Patients Nsclc | Initial Response | Cns Metastases |
Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
[ PUBLICATION ]
BACKGROUND: Vascular endothelial growth factor inhibitors have corticosteroid-sparing effects in patients with high-grade gliomas. We assessed corticosteroid use in patients with recurrent glioblastoma treated with bevacizumab (BEV) in the BRAIN study (J Clin Oncol 2009;27:4733-4740).
METHODS: BRAIN was a phase II, multicenter, randomized, noncomparative trial of BEV alone (n = 85) or in combination with irinotecan (CPT-11) (n = 82) in adults with recurrent glioblastoma. Median ...
| Known for Monoclonal Antibodies | Recurrent Glioblastoma | Bevacizumab Bev | Corticosteroid Dose | Progressionfree Survival |
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma
[ PUBLICATION ]
BACKGROUND: Trastuzumab, which is a large monoclonal antibody that is efficacious in the treatment of patients with HER-2/neu-overexpressing, metastatic breast carcinoma, does not penetrate the blood-brain barrier and, thus, may allow the brain to become a sanctuary site for micrometastases. Few studies have compared the risk of central nervous system (CNS) metastases in patients treated with or without trastuzumab.
METHODS: The authors conducted a retrospective cohort study that ...
| Known for Trastuzumab Therapy | Breast Carcinoma | Cns Metastases | Monoclonal Antibodies | Central Nervous |
PURPOSE: To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL).
PATIENTS AND METHODS: Twenty-eight patients received induction chemotherapy using high-dose systemic methotrexate (3.5 g/m2) and cytarabine (3 g/m2 daily for 2 days). Fourteen patients with chemosensitive disease evident on neuroimaging then received high-dose ...
| Known for Autologous Stem | Dose Chemotherapy | Intensive Methotrexate | Cell Rescue | Primary Cns |
Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma
[ PUBLICATION ]
PURPOSE: Our goals were to evaluate the safety of adding rituximab to methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of induction chemotherapy improve the complete response (CR) rate, and examine effectiveness and toxicity of reduced-dose whole-brain radiotherapy (WBRT) after CR.
PATIENTS AND METHODS: Thirty patients (17 women; median age, 57 years; median Karnofsky performance score, 70) were treated with five to seven cycles of ...
| Known for Monoclonal Antibodies | Wbrt Patients | Induction Chemotherapy | Cns Lymphoma | Brain Radiotherapy |
We have tested the predictive value of apparent diffusion coefficient (ADC) histogram analysis in stratifying progression-free survival (PFS) and overall survival (OS) in bevacizumab-treated patients with recurrent glioblastoma multiforme (GBM) from the multi-center BRAIN study. Available MRI’s from patients enrolled in the BRAIN study (n = 97) were examined by generating ADC histograms from areas of enhancing tumor on T1 weighted post-contrast images fitted to a two normal distribution ...
| Known for Recurrent Gbm | Apparent Diffusion | Histogram Analysis | Pfs Patients | Low Adcl |
(18)F-Fluorodeoxyglucose (FDG) PET has become an important tool in the management of non-Hodgkin's lymphoma (NHL), but its role in the evaluation of primary CNS lymphoma (PCNSL) has not been established. We investigated the ability of body FDG PET to detect systemic disease in the staging and restaging of PCNSL. The records of 166 PCNSL patients seen at Memorial Sloan-Kettering Cancer Center were examined. Forty-nine patients who underwent body FDG PET for staging of PCNSL were ...
| Known for Fdg Pet | Central Nervous | Systemic Disease | Lymphoma Pcnsl | Cns Relapse |
PURPOSE: To determine the maximum-tolerated dose (MTD), toxicities, and clinical effect of tipifarnib, a farnesyltransferase (FTase) inhibitor, in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs). This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs.
PATIENTS AND METHODS: Recurrent malignant glioma patients were treated with tipifarnib using an interpatient dose-escalation scheme. ...
| Known for Patients Eiaeds | Antiepileptic Drugs | Malignant Glioma | Tipifarnib Mtd | Brain Tumor |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
[ PUBLICATION ]
High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to address chemoresistance and overcome the blood-brain barrier. In this single-center phase-2 study, newly diagnosed PCNSL patients received 5 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m(2)), procarbazine, and ...
| Known for Dose Chemotherapy | Autologous Stem | Diagnosed Primary | Median Pfs | Cns Lymphoma |
Key People For Recurrent Glioblastoma
Lauren Eileen Abrey:Expert Impact
Concepts for whichLauren Eileen Abreyhas direct influence:Recurrent glioblastoma, Central nervous, Primary cns lymphoma, Brain metastases, Rano criteria, Newly diagnosed glioblastoma, Disease recurrence, Monoclonal antibodies.
Lauren Eileen Abrey:KOL impact
Concepts related to the work of other authors for whichfor which Lauren Eileen Abrey has influence:Brain metastases, Central nervous, Recurrent glioblastoma, Elderly patients, Malignant gliomas, Primary cns lymphoma, Radiation therapy.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |